AXP vs EBS · P/E 20, rev $41.30B vs rev $1.04B
American Express Company (AXP) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
American Express Company (AXP) is a credit services company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported AXP revenue for 2025-12-31 was $41.30B. Net income was $10.83B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. AXP currently screens at market cap $215.94B and trailing P/E 19.8.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
AXP currently screens at market cap $215.94B and trailing P/E 19.8. EBS currently screens at market cap $416.4M.
Not investment advice. Open the AXP and EBS stock pages for the full models.
Not investment advice.